Development of heparinase for coagulation testing

Since January 2019, MBS-Technologiya LLC has been implementing a project to develop recombinant heparinase I – a necessary component of many coagulological tests used to remove heparin from plasma samples before conducting studies.

The use of heparin as an anticoagulant leads to the inability to adequately conduct such tests as ACTV, Thromboelastography and others. Pretreatment of the studied plasma with recombinant heparinase leads to destruction of heparin residues and restoration of coagulological parameters of the sample.